Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Tabbo F, Guerrera F, van den Berg A, Gaudiano M, Maletta F, Bessone L, et al. Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways. Eur J Cancer. 2021;144:17-30.

Kasashima H, Duran A, Martinez-Ordoñez A, Nakanishi Y, Kinoshita H, Linares JF, et al. Stromal SOX2 Upregulation Promotes Tumorigenesis through the Generation of a SFRP1/2-Expressing Cancer-Associated Fibroblast Population. Dev Cell. 2021;56(1):95-110.e10.

Gaebler C, Wang Z, Lorenzi JC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv. 2021.

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat Commun. 2021;12(1):3372.

Satlin MJ, Zucker J, Baer BR, Rajan M, Hupert N, Schang LM, et al. Changes in SARS-CoV-2 viral load and mortality during the initial wave of the pandemic in New York City. PLoS One. 2021;16(11):e0257979.

Chourasia M, Koppula PR, Battu A, Ouseph MM, Singh AK. EGCG, a Green Tea Catechin, as a Potential Therapeutic Agent for Symptomatic and Asymptomatic SARS-CoV-2 Infection. Molecules. 2021;26(5).

Fragliasso V, Tameni A, Inghirami G, Mularoni V, Ciarrocchi A. Cytoskeleton Dynamics in Peripheral T Cell Lymphomas: An Intricate Network Sustaining Lymphomagenesis. Front Oncol. 2021;11:643620.

Rendeiro AF, Ravichandran H, Bram Y, Chandar V, Kim J, Meydan C, et al. The spatial landscape of lung pathology during COVID-19 progression. Nature. 2021;593(7860):564-569.

Kondo M, Simon MS, Westblade LF, Jenkins SG, N Babady E, Loo AS, et al. Implementation of infectious diseases rapid molecular diagnostic tests and antimicrobial stewardship program involvement in acute-care hospitals. Infect Control Hosp Epidemiol. 2021;42(5):609-611.

Cho C, Hilden P, Avecilla ST, Barker JN, Castro-Malaspina H, Giralt SA, et al. Combining the Disease Risk Index and Hematopoietic Cell Transplant Co-Morbidity Index provides a comprehensive prognostic model for CD34+-selected allogeneic transplantation. Adv Cell Gene Ther. 2021;4(1).